Associate Director, Translational Science

The Jounce Translational Science Platform is key to our understanding of tumor immunobiology and is instrumental in our approach to identifying and prioritizing targets and developing biomarker strategies to enable us to select the right patients for our immunotherapeutics. We are seeking a highly motivated and accomplished leader for one of our translational science groups, of approximately 9 researchers with a focus on IHC, flow cytometry and ex vivo tumor histoculture, within the larger translational science efforts at Jounce Therapeutics.   The leader of this team will be a strong translational scientist with significant experience in oncology and/or immunology, and preferably immuno-oncology biologics drug development.  The successful applicant will be responsible for establishing novel biomarker strategies, including identification, development and execution of translational biomarker plans for multiple biologics programs in the Jounce pipeline from time of discovery of a target through to clinical biomarkers for patient and indication selection. The individual will be also be responsible for establishing and managing multiple academic collaborations with leading clinical investigators.  This position will report directly to the VP of Discovery and Translational Sciences and will be expected to interact closely with Discovery, Regulatory and Clinical groups within Jounce as well as with external experts.

Responsibilities:

Responsible for developing and supporting the translational and biomarker strategy for multiple biologics program(s) from early discovery through to patient and indication selection strategies in the clinic.

  • Leading a group of 9 researchers (both PhD and non-PhD) to identify, assess and develop biomarkers to support programs from discovery through to patient and indication selection in the clinic.
  • Generating key translational data using IHC, flow cytometry, and ex-vivo culture systems to guide indication selection and identify target patient populations for Jounce programs.
  • Working closely with discovery scientists and other members of the larger Translational Science effort, particularly the bioinformatics/RNA-based team, to develop and deliver on integrated translational plans to support programs from early preclinical to clinical stage.
  • Delivering biomarkers for assessment in clinical studies based on an integrated translational sciences approach with best available science and technologies, including supporting pharmacodynamics, predictive clinical biomarker and CDx strategy implementation.
  • Developing suitable assays for transfer to CLIA/CAP,GLP, GCP settings, and implementing vendor surveillance management over contract research organizations (CROs) to ensure the outsourced project(s) adherence to scope of work within quality, timelines and budget.
  • Contributing to clinical biomarker/Companion Diagnostics (CDx) assay development, validation, timely transfer to clinical settings, monitoring and sample analyzing, data interpretation & evaluation.
  • Participating in regulatory submission documents, internal documents preparation and scientific publication.
  • Establishing and managing key clinical and academic collaborations to facilitate access to clinical samples to support the Translational Sciences platform development.

Qualifications:

  • Doctoral degree (PhD.), M.D.,  or equivalent, post-doctoral experience and at least 8+ years of relevant industry experience in developing and implementing translational biomarker strategies with a track record of success in the pharma industry and/or academia.
  • A strong background in cancer biology or immunology, preferably immuno-oncology with a broad understanding of biomarker applicability in early and late stage biologics drug development.
  • Strong leadership and proven track record in management and career development of more junior employees.
  • Strategic thinker, with strong verbal and written communication skills.
  • Ability to function in high-paced, team-oriented setting including proven track record of working in cross-functional teams.
  • Experience with establishing and managing external academic research collaborations and external CRO’s involved in validating biomarkers pre-clinically, and, if possible, in biomarker assay implementation in early clinical development (phase 1 and 2).
  • Experience in writing/supporting sections of regulatory filings focused on biomarker plans (e.g for IND’s, BLA’s, IDE’s).

Preferred Qualifications:

  • Demonstrated technical excellence and expertise in translational medicine; including hands-on experience taking biologics, particularly monoclonal antibodies, through preclinical to clinical development is preferred
  • Strong understanding of biomarker technologies important to biologics drug development with specific technical expertise in either IHC, flow cytometry or ex vivo organ culture preferred

Knowledge of IHC-based CDx assays an advantage